CLL: FCR-Dosisreduktion vermeiden

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).

Although fludarabine, cyclophosphamide, and rituximab (FCR) together are established as a standard first-line treatment of younger patients with chronic lymphocytic leukemia (CLL), there is little information to guide the management of patients with CLL refractory to, or who have relapsed after, receiving frontline FCR treatment. To define optimal salvage strategy and identify patients unsuitab...

An accounting model for assessing FCR

Recent European legislation adopts the concept of Full-cost recovery (FCR) as the guiding line for pricing of environmental services. In this paper, the meaning of the FCR concept is analysed and the economic rationale for its application is discussed. The basic idea developed is that FCR is a misleading concept, since costs are by definition recovered, and the problem becomes to assess how it ...

Antibody-Mediated, FcR-Dependent Enhancement of Cytotoxicity

CLL: a supplementary question?

In this issue of Blood, Shanafelt and colleagues provide the first evidence that vitamin D deficiency is a risk factor for disease progression in chronic lymphocytic leukemia (CLL). Their findings imply that dietary vitamin D supplementation could potentially modify the natural history of this incurable disease.

Telomere disrupts, CLL progresses.

In this issue of Blood, Lin and colleagues address in detail the nature and severity of telomere disruption in chronic lymphocytic leukemia (CLL).1 Using sophisticated methods for telomere length determination, the authors show that critical telomere shortening occurs in a proportion of CLL samples and correlates with the presence of large-scale genomic rearrangements occurring in telomeric reg...